<DOC>
	<DOCNO>NCT00830609</DOCNO>
	<brief_summary>The rate sustain virological response ( SVR ) patient chronic hepatitis C , genotype 3 , high viral load without rapid virological response ( RNA-HCV negative week 4 ) low . Standard care patient include treatment weekly peginterferon plus 800 mg/day ribavirin ( RBV ) . Extended treatment 48 week provide clinical benefit standard duration . The main hypothesis high dose ribavirin may better term SVR standard dose .</brief_summary>
	<brief_title>High Dose Versus Standard Dose Ribavirin Patients With Chronic Hepatitis C , Genotype 3</brief_title>
	<detailed_description>Aims : 1 . Efficacy 1.1 ) Rate RNA-HCV negative week 4 24 arm . 1.2 ) Rate SVR arm . 2 . Safety 2.1 ) Rate adverse effect arm . Design : Randomized controlled trial . Patients randomly allocate three arm : Arm A : Peginterferon α-2a ( 180 μg/week ) SC . plus Ribavirin ( 800 mg/day ) p.o . 24 week . Arm B : Peginterferon α-2a ( 180 μg/week ) plus Ribavirin ( 1600 mg/day ) support Epoetin β ( 450 IU/kg/week ) SC 4 week : B1.- If RNA-HCV undetectable week 4 , standard care continue ( Peginterferon α-2a , 180 μg/wee plus Ribavirin ( 800 mg/day ) 20 additional week ) . B2.- If RNA-HCV detectable week 4 , treatment continue peginterferon α-2a ( 180 μg/week ) plus RBV ( 1,600 mg/day ) plus Epoetin β ( 450 UI/kg/week ) 20 additional week . Sample size : 111 patient . To increase SVR 50 % 75 % . Beta : 0.1 ; alfa : 0.05 ; Loss : 15 % . Randomization 1:2 , 37 patient Group A 74 patient group B .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>HCV Genotype 3 RNAHCV &gt; &gt; 600.000 IU/ml . Compromise use contraceptive measure treatment 6 month end treatment . Pregnant breastfeeding female . Concurrent treatment antineoplastic immunomodulatory agent , include corticosteroid radiation therapy last 6 month start trial Treatment investigational drug &lt; 6 week start trial Chronic liver disease hepatitis C. Evidence hepatocellular carcinoma . Evidence carcinoma hepatocellular Decompensated liver disease Baseline Neutrophil count &lt; 1500/cc ; Platelet count &lt; 90,000/cc Baseline Hemoglobin &lt; 12 g/dL female &lt; 13 g/dL male . Increased risk anemia ( Eg , thalassemia , spherocytosis.. ) . Ischemic heart disease cerebrovascular disease . Serum creatinine &gt; 1.5 time upper limit normality . History severe psychiatric condition ( Major antidepressives neuroleptic drug require major depression psychosis ) , suicide attempt psychiatric disability . History convulsive disorder . Immunological condition . Chronic Obstructive Lung Disease limit functionality Severe heart disease congestive cardiac insufficiency cardiopathy grave . Advanced atherosclerosis Solid organ bone marrow transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Genotype 3</keyword>
	<keyword>High viral load</keyword>
</DOC>